Similar articles

• [Management of acute myocardial infarction: What remains of intravenous thrombolysis?].

  Bonnet JL, Bonnet G. Bonnet JL, et al. Presse Med. 2011 Jun;40(6):611-4. doi: 10.1016/j.lpm.2011.02.040. Epub 2011 May 12. Presse Med. 2011. PMID: 21570245 Review. French.
• ["Smoker's paradox" and reperfusion's strategy in acute myocardial infarction].

  Addad F, Dridi Z, Jemmali M, Mzoughi K, Hassine M, Ghrissi I, Hamdi S, Mahjoub M, Betbout F, Ben Farhat M, Gamra H. Addad F, et al. Ann Cardiol Angeiol (Paris). 2010 Aug;59(4):183-9. doi: 10.1016/j.ancard.2010.07.006. Epub 2010 Aug 3. Ann Cardiol Angeiol (Paris). 2010. PMID: 20709314 French.
• Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction.

  Huber K, De Caterina R, Kristensen SD, Verheugt FW, Montalescot G, Maestro LB, Van de Werf F; Task Force on Pre-hospital Reperfusion Therapy of the Working Group on Thrombosis of the ESC. Huber K, et al. Eur Heart J. 2005 Oct;26(19):2063-74. doi: 10.1093/eurheartj/ehi413. Epub 2005 Jul 29. Eur Heart J. 2005. PMID: 16055497 Review. No abstract available.
• Acceptable reperfusion delay to prefer primary angioplasty over fibrin-specific thrombolytic therapy is affected (mainly) by the patient's mortality risk: 1 h does not fit all.

  Tarantini G, Razzolini R, Napodano M, Bilato C, Ramondo A, Iliceto S. Tarantini G, et al. Eur Heart J. 2010 Mar;31(6):676-83. doi: 10.1093/eurheartj/ehp506. Epub 2009 Nov 27. Eur Heart J. 2010. PMID: 19946106 Review.
• [Thrombolytic (fibrinolytic) agents for treatment of ischemic heart disease].

  Nagao K, Kanmatsuse K. Nagao K, et al. Nihon Rinsho. 2003 Apr;61 Suppl 4:641-6. Nihon Rinsho. 2003. PMID: 12735044 Review. Japanese. No abstract available.